Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Goodwill (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Goodwill for 3 consecutive years, with $22.9 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Goodwill changed 0.0% year-over-year to $22.9 million, compared with a TTM value of $22.9 million through Dec 2024, changed 0.0%, and an annual FY2024 reading of $22.9 million, changed 0.0% over the prior year.
  • Goodwill was $22.9 million for Q4 2024 at Xeris Biopharma Holdings, roughly flat from $22.9 million in the prior quarter.
  • Across five years, Goodwill topped out at $22.9 million in Q1 2022 and bottomed at $22.9 million in Q1 2022.
  • Average Goodwill over 3 years is $22.9 million, with a median of $22.9 million recorded in 2022.
  • Peak annual rise in Goodwill hit 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
  • Year by year, Goodwill stood at $22.9 million in 2022, then changed by 0.0% to $22.9 million in 2023, then changed by 0.0% to $22.9 million in 2024.
  • Business Quant data shows Goodwill for XERS at $22.9 million in Q4 2024, $22.9 million in Q1 2024, and $22.9 million in Q4 2023.